Dextrin-rhEGF conjugates as bioresponsive nanomedicines for wound repair

被引:94
作者
Hardwicke, Joseph [1 ,2 ]
Ferguson, Elaine L. [2 ]
Moseley, Ryan [1 ]
Stephens, Phil [1 ]
Thomas, David W. [1 ]
Duncan, Ruth [2 ]
机构
[1] Cardiff Univ, Wound Biol Grp, Cardiff Inst Tissue Engn & Repair Tissue Engn & R, Sch Dent, Cardiff CF14 4XY, Wales
[2] Welsh Sch Pharm, Ctr Polymer Therapeut, Cardiff CF10 3XF, Wales
基金
英国工程与自然科学研究理事会;
关键词
Dextrin-rhEGF conjugate; Wound repair; PUMPT; Polymer therapeutics; Nanomedicine;
D O I
10.1016/j.jconrel.2008.07.023
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Growth factors are known to act in concert to promote wound repair, but their topical application rarely leads to a significant clinical improvement of chronic wounds due to premature inactivation in wound environment. The aim of this study was to synthesise a polymer-growth factor conjugate and investigate whether the novel concept called Polymer-masking-UnMasking-Protein Therapy (PUMPT) might be used to generate bioresponsive polymer therapeutics as nanomedicines able to promote tissue repair. Succinoylated dextrin (similar to 85,000 g/mol; similar to 19 mol% succinoylation), and rhEGF were chosen as a first model combination. The conjugate synthesised contained similar to 16%wt rhEGF and <1% free protein. It exhibited increased stability towards proteolytic degradation by trypsin and the clinically relevant enzyme neutrophil elastase. The dextrin component was degraded on addition of alpha-amylase leading to sustained release of free rhEGF over time (52.7% release after 168 h). When biological activity was assessed ( +/-alpha-amylase) in proliferation assays using epidermoid carcinoma (HEp2) cells and HaCaT keratinocytes, as anticipated, polymer conjugation reduced rhEGF bioactivity (p=0.0035). However, exposure to physiological concentrations of alpha-amylase triggered dextrin degradation and this led to protein unmasking with restoration of bioactivity to the level seen for unmodified rhEGE Indeed, prolongation of HEp2 proliferation was observed over 8 days. The inability of dextrin, succinoylated dextrin or alpha-amylase alone to induce proliferative effects, and the ability of alpha-amylase-exposed dextrin-rhEGF to induce phosphorylation of the epidermal growth factor receptor (EGFR) in HEp2 cells confirmed a mechanism of action by stimulation of classical signal transduction pathways. These observations suggest that this dextrin-rhEGF, and other dextrin-growth factor conjugates have potential for further development as bioresponsive nanomedicines for tissue repair. (C) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:275 / 283
页数:9
相关论文
共 39 条
[11]   TOPICAL USE OF HUMAN RECOMBINANT EPIDERMAL GROWTH-FACTOR (H-EGF) IN VENOUS ULCERS [J].
FALANGA, V ;
EAGLSTEIN, WH ;
BUCALO, B ;
KATZ, MH ;
HARRIS, B ;
CARSON, P .
JOURNAL OF DERMATOLOGIC SURGERY AND ONCOLOGY, 1992, 18 (07) :604-606
[12]   Icodextrin - A review of its use in peritoneal dialysis [J].
Frampton, JE ;
Plosker, GL .
DRUGS, 2003, 63 (19) :2079-2105
[13]  
FRANCESCO M, 2008, ADV DRUG DELIVERY RE, V60, P1
[14]  
Goldman Robert, 2004, Adv Skin Wound Care, V17, P24, DOI 10.1097/00129334-200401000-00012
[15]   Effect of pegylation on pharmaceuticals [J].
Harris, JM ;
Chess, RB .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (03) :214-221
[16]   Regulation of keratinocyte function by growth factors [J].
Hashimoto, K .
JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 24 :S46-S50
[17]  
HERRICK SE, 1992, AM J PATHOL, V141, P1085
[18]  
Hong Joon Pio, 2006, Int Wound J, V3, P123, DOI 10.1111/j.1742-4801.2006.00187.x
[19]   Recombinant human epidermal growth factor (EGF) to enhance healing for diabetic foot ulcers [J].
Hong, JP ;
Jung, HD ;
Kim, YW .
ANNALS OF PLASTIC SURGERY, 2006, 56 (04) :394-398
[20]   A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution [J].
Hosie, KB ;
Kerr, DJ ;
Gilbert, JA ;
Downes, M ;
Lakin, G ;
Pemberton, G ;
Timms, K ;
Young, A ;
Stanley, A .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2003, 29 (03) :254-260